Literature DB >> 14744807

Regional haemodynamic effects of cyclosporine A, tacrolimus and sirolimus in conscious rats.

S M Gardiner1, J E March, P A Kemp, B Fallgren, T Bennett.   

Abstract

1. The observation that the immunosuppressants, cyclosporine A (CsA) and tacrolimus, have pressor effects, but sirolimus does not, has led to an hypothesis that generalised sympathoexcitation, resulting from inhibition of calcineurin by CsA and tacrolimus underlies their pressor effects, because sirolimus does not inhibit calcineurin. It is unknown if sirolimus has haemodynamic actions not accompanied by a pressor effect, and whether or not the pressor effects of CsA and tacrolimus are accompanied by similar haemodynamic changes. Therefore, the first aim of our studies was to investigate these possibilities in conscious, chronically-instrumented, male, Sprague-Dawley rats. 2. CsA (5.9 mg kg(-1) bolus i.v.) caused rapid-onset, prolonged hypertension, tachycardia and mesenteric vasoconstriction. There was a slower onset renal vasoconstriction, but no significant change in hindquarters vascular conductance; all the effects of CsA were significantly greater than those of vehicle. CsA given by infusion (over 30 min or 2 h) caused changes qualitatively similar to those above. Repeated administration of CsA over 4 days did not enhance its cardiovascular effects. 3. Pretreatment with the angiotensin (AT(1)) receptor antagonist, losartan, and the endothelin (ET(A) and ET(B)) receptor antagonist, SB 209670, reduced the pressor and mesenteric vasoconstrictor effects of CsA. Additional administration of the alpha-adrenoceptor antagonist, phentolamine, completely inhibited the cardiovascular effects of CsA. 4. Tacrolimus (450 microg kg(-1) bolus i.v.) caused similar peak pressor and tachycardic effects to CsA, but these were much slower in onset, and were maximal when there were no significant regional vasoconstrictions, indicating that the pressor effect was probably due to a rise in cardiac output. However, although propranolol reversed the tachycardic effect of tacrolimus, it did not influence the pressor response. 5. Sirolimus (450 microg kg(-1) bolus i.v.) had no tachycardic action, and only a modest, transient pressor effect, accompanied by equally brief reductions in renal, mesenteric, and hindquarters vascular conductances. 6. The differences between the regional haemodynamic profiles of equipressor doses of CsA and tacrolimus, and the finding that sirolimus has significant cardiovascular actions, indicate that generalised sympathoexcitation, resulting from calcineurin inhibition (with CsA and tacrolimus), is unlikely to be the sole explanation of their pressor effects.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14744807      PMCID: PMC1574241          DOI: 10.1038/sj.bjp.0705659

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  52 in total

1.  Dose-dependent effect of cyclosporin on renal arterial resistance in dogs.

Authors:  M Carrier; F Tronc; D Stewart; L C Pelletier
Journal:  Am J Physiol       Date:  1991-12

2.  FK506 does not affect cardiac contractility and adrenergic response in vitro.

Authors:  H Milting; P M Janssen; T Wangemann; H Kögler; E Domeier; T Seidler; K Hakim; M Grapow; O Zeitz; J Prestle; H R Zerkowski
Journal:  Eur J Pharmacol       Date:  2001-11-02       Impact factor: 4.432

3.  Intravenous cyclosporine activates afferent and efferent renal nerves and causes sodium retention in innervated kidneys in rats.

Authors:  N G Moss; S L Powell; R J Falk
Journal:  Proc Natl Acad Sci U S A       Date:  1985-12       Impact factor: 11.205

4.  Direct vascular smooth muscle contractile effect of cyclosporin A and its vehicle in rabbit isolated arteries.

Authors:  E Yariş; M Tuncer; S O Kayaalp; M Ilhan
Journal:  Arch Int Pharmacodyn Ther       Date:  1994 Mar-Apr

5.  Mechanism of cyclosporine-induced sympathetic activation and acute hypertension in rats.

Authors:  T Lyson; D M McMullan; L D Ermel; B J Morgan; R G Victor
Journal:  Hypertension       Date:  1994-05       Impact factor: 10.190

6.  Stimulation of airway sensory nerves by cyclosporin A and FK506 in guinea-pig isolated bronchus.

Authors:  S Harrison; S Reddy; C P Page; D Spina
Journal:  Br J Pharmacol       Date:  1998-12       Impact factor: 8.739

7.  Cyclosporine therapy after cardiac transplantation causes hypertension and renal vasoconstriction without sympathetic activation.

Authors:  D Kaye; J Thompson; G Jennings; M Esler
Journal:  Circulation       Date:  1993-09       Impact factor: 29.690

8.  Physiologically based pharmacokinetics of cyclosporine A: extension to tissue distribution kinetics in rats and scale-up to human.

Authors:  R Kawai; D Mathew; C Tanaka; M Rowland
Journal:  J Pharmacol Exp Ther       Date:  1998-11       Impact factor: 4.030

9.  Cyclosporine causes sympathetically mediated elevations in arterial pressure in rats.

Authors:  B J Morgan; T Lyson; U Scherrer; R G Victor
Journal:  Hypertension       Date:  1991-10       Impact factor: 10.190

10.  Effects of an endothelin receptor antagonist in rats with cyclosporine-induced hypertension.

Authors:  Y Takeda; I Miyamori; P Wu; T Yoneda; K Furukawa; R Takeda
Journal:  Hypertension       Date:  1995-12       Impact factor: 10.190

View more
  13 in total

1.  BATF inhibition prevent acute allograft rejection after cardiac transplantation.

Authors:  Bo Yang; Fan He; Chen Dai; Rumeng Tan; Dongxia Ma; Zhimin Wang; Bo Zhang; Jincheng Feng; Lai Wei; Hua Zhu; Zhishui Chen
Journal:  Am J Transl Res       Date:  2016-08-15       Impact factor: 4.060

2.  Low-salt diet and cyclosporine nephrotoxicity: changes in kidney cell metabolism.

Authors:  Jelena Klawitter; Jost Klawitter; Volker Schmitz; Nina Brunner; Amanda Crunk; Kyler Corby; Jamie Bendrick-Peart; Dieter Leibfritz; Charles L Edelstein; Joshua M Thurman; Uwe Christians
Journal:  J Proteome Res       Date:  2012-10-11       Impact factor: 4.466

3.  Everolimus treatment downregulates renocortical cyclooxygenase-2 expression in the rat kidney.

Authors:  Klaus Höcherl; Corina Hensel; Bettina Ulbricht; Bernhard K Krämer
Journal:  Br J Pharmacol       Date:  2005-08       Impact factor: 8.739

4.  Pioglitazone abrogates cyclosporine-evoked hypertension via rectifying abnormalities in vascular endothelial function.

Authors:  Mahmoud M El-Mas; Hanan M El-Gowelli; Khaled S Abd-Elrahman; Evan I Saad; Abdel-Galil A Abdel-Galil; Abdel A Abdel-Rahman
Journal:  Biochem Pharmacol       Date:  2010-11-27       Impact factor: 5.858

Review 5.  Assessment and management of hypertension in transplant patients.

Authors:  Matthew R Weir; Ellen D Burgess; James E Cooper; Andrew Z Fenves; David Goldsmith; Dianne McKay; Anita Mehrotra; Mark M Mitsnefes; Domenic A Sica; Sandra J Taler
Journal:  J Am Soc Nephrol       Date:  2015-02-04       Impact factor: 10.121

6.  Safety and tolerability of cyclosporin a in severe traumatic brain injury patients: results from a prospective randomized trial.

Authors:  Anna Teresa Mazzeo; Gretchen M Brophy; Charlotte B Gilman; Oscar Luís Alves; Jaime R Robles; Ronald L Hayes; John T Povlishock; M Ross Bullock
Journal:  J Neurotrauma       Date:  2009-12       Impact factor: 5.269

7.  Urine metabolites reflect time-dependent effects of cyclosporine and sirolimus on rat kidney function.

Authors:  Jost Klawitter; Jamie Bendrick-Peart; Birgit Rudolph; Virginia Beckey; Jelena Klawitter; Manuel Haschke; Christopher Rivard; Laurence Chan; Dieter Leibfritz; Uwe Christians; Volker Schmitz
Journal:  Chem Res Toxicol       Date:  2009-01       Impact factor: 3.739

8.  Effect of low-dose tacrolimus with mycophenolate mofetil on renal function following liver transplantation.

Authors:  Jing-Cheng Hao; Wen-Tao Wang; Lu-Nan Yan; Bo Li; Tian-Fu Wen; Jia-Yin Yang; Ming-Qing Xu; Ji-Chun Zhao; Yong-Gang Wei
Journal:  World J Gastroenterol       Date:  2014-08-28       Impact factor: 5.742

9.  Regional haemodynamic effects of cyclosporine A, tacrolimus and sirolimus in conscious rats.

Authors:  S M Gardiner; J E March; P A Kemp; B Fallgren; T Bennett
Journal:  Br J Pharmacol       Date:  2004-01-26       Impact factor: 8.739

Review 10.  Hypertension after kidney transplantation: a pathophysiologic approach.

Authors:  Beje Thomas; David J Taber; Titte R Srinivas
Journal:  Curr Hypertens Rep       Date:  2013-10       Impact factor: 5.369

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.